Innate Pharma 2023 Financial Calendar

Rhea-AI Summary

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has released its 2023 financial calendar, scheduling key financial reports throughout the year. Important dates include:

• March 23, 2023: Publication of 2022 financial statements
• May 10, 2023: 1Q2023 revenue announcement
• September 14, 2023: Half-year financial statements
• November 14, 2023: 3Q2023 revenue release

All reports will be made public before market open CET. For more details about the company and its activities, visit the website.

Positive

• Innate Pharma has scheduled multiple financial reports for 2023, enhancing transparency and investor communication.
• The inclusion of quarterly revenue updates (1Q and 3Q) may provide shareholders with timely insights into the company's financial performance.

Negative

• None.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2023 financial calendar:

March 23, 2023:		Publication of 2022 financial statements
May 10, 2023:		Publication of revenue for 1Q2023
May 12, 2023:		Annual General Shareholders Meeting
September 14, 2023:		Publication of half year financial statements
November 14, 2023:		Publication of revenue for 3Q2023

All financial reports are released before market open CET.

All corporate information, such as the Company’s financial statements and corporate presentations, is available in the Investors section on https://www.innate-pharma.com.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005744/en/

For additional information, please contact:



Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr



Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

What are the key dates in Innate Pharma's 2023 financial calendar?

Key dates include March 23 for 2022 financial statements, May 10 for 1Q2023 revenue, September 14 for half-year financials, and November 14 for 3Q2023 revenue.

When will Innate Pharma release its 2022 financial statements?

Innate Pharma will release its 2022 financial statements on March 23, 2023.

What is the significance of Innate Pharma's financial reporting schedule for investors?

The financial reporting schedule provides investors with regular updates on the company's performance, supporting informed investment decisions.

Where can I find more information about Innate Pharma's financial reports?

More information can be found in the Investors section of Innate Pharma's official website.